Development, preclinical, and early clinical data on the GIP/GLP-1 receptor agonist tirzepatide Among the GIP/GLP-1 receptor agonists, tirzepatide (LY3298176) is the compound that is the most advanced in development and the first substance in this class that has received approval for the therapy of T2D by the FDA in May 2022 (manufacturer Eli Lilly Comp., trade name Mounjaro ) (5355)
For example, semaglutide can help you lose 15% of your weight in 68 weeks, while an older drug, Contrave, has been shown to result in closer to a 5% weight loss
So its, you know, I dont want to tell people completely avoid the brand name, but for someone like me, if I were, or you, if I were to have started at that dose, I would have been projectile vomiting and in a whole, a world of hurt
General Cardiometabolic Health Blood Pressure Control: GLP-1 agonists like Semaglutide have effectively controlled blood pressure, benefiting cardiovascular health
The statistical significance of the results from the meta-regression was consistent with the subgroup analyses
Frequently Asked Questions What is an HSA or FSA